Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/20523" target="_blank" data-smartkarma-citation="entities:20523:1">Sime Darby Berhad (SIME MK)</a> is placing US$570m primary shares after market close today, in an attempt to lower its leverage and fund its capex plan. In this insight, we will look at fundamentals of the company and score the deal in our quantitative ECM framework.</p><h2>Placement Specifics</h2><ul>
<li>Company Name: Sime Darby Bhd</li>
<li>Ticker: SIME MK Equity</li>
<li>Primary placement -Accelerated Bookbuild</li>
<li>Settlement is longer than normal, with stock settling on 14 Oct, 2016</li>
<li>Indicative deal price -7.4-7.45</li>
<li>Last Traded Price: MYR7.61</li>
<li>…</li>
</ul>

Sime Darby Berhad (SIME MK) is placing US$570m primary shares after market close today, in an attempt to lower its leverage and fund its capex plan. In this insight, we will look at fundamentals of the company and score the deal in our quantitative ECM framework.Placement Specifics
Company Name: Sime Darby Bhd
Ticker: SIME MK Equity
Primary placement -Accelerated Bookbuild
Settlement is longer than normal, with stock settling on 14 Oct, 2016
Indicative deal price -7.4-7.45
Last Traded Price: MYR7.61
…


Sime Darby Placement: Ageing Trees Are The Bugbears